Medindia

X

High-Dose Influenza Vaccine with Evidence of Superior Efficacy* in Older Adults: Now in Canada

Thursday, October 13, 2016 Senior Health News J E 4
Advertisement

1 Public Health Agency of Canada (2016). An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): A Review of the Literature of High Dose Seasonal Influenza Vaccine for Adults 65 Years and Older.

2 Product Monograph: FLUZONE® High-Dose Influenza Virus Vaccine Trivalent Types A and B (Split Virion). Sanofi Pasteur.  Approved May 2016

3 Public Health Agency of Canada (2016). An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2016-2017.

4 DiazGranados, C.A. et al. (2014). Efficacy of high-dose versus standard-dose influenza vaccine in older adults. The New England Journal of Medicine 371, 635-645.

5 Centers of Disease Control and Prevention. People at High Risk of Developing Flu Related Complications. http://www.cdc.gov/flu/about/disease/high_risk.htm. Accessed September 2016.

6 Udell J.A., et al. (2015). Does influenza vaccination influence cardiovascular complications? Expert Rev Cardiovasc Ther. 13:593-596.

*Against lab-confirmed influenza illness compared to a standard dose influenza vaccine

FLUZONE® Influenza Virus Vaccine Trivalent Types A and B (Split Virion)

‡ FLUZONE® High-Dose Influenza Vaccine is not indicated to treat or prevent heart attacks or stroke.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Interpace Diagnostics Launches New Services for In...
S
Can-Fite Submits Protocol for Phase II Trial of CF...